Related Experiment Video
Updated: Jan 11, 2026
Inducement and Evaluation of a Murine Model of Experimental Myopia
Published on: January 22, 2019
One-Year Myopia Control Efficacy of a New Defocus Spectacle Lens: A Randomized Clinical Trial
Xiaotong Han1, Yurui Zhang1, Ling Jin1
1State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, Guangdong, China.
Purpose:
To evaluate the efficacy and safety of the new defocus spectacle lens in preventing myopia progression compared with the conventional single-vision spectacle lens (SVL).
Design:
A randomized, open-label, controlled clinical trial.
Subjects:
Children aged 6 to 14 years with a cycloplegic spherical equivalent refraction (SER) of -1.00 to -3.50 diopters (D) in both eyes were enrolled.
Methods:
Eligible participants were randomly assigned in a 1:1 ratio to receive either the novel defocus spectacle lens (MYOGEN) or the SVL. Data from the right eyes at the 12-month follow-up were used for the current analysis.
Main Outcome Measures:
The primary outcome was the 1-year change in SER from baseline to 12 months. Secondary outcomes included changes in axial length (AL), choroidal thickness, subjective visual quality scores, and daily spectacle wear time. Axial length was designated as the main secondary outcome due to its close relationship with myopia progression.
Results:
A total of 85 patients were assigned to the MYOGEN group and 89 to the SVL group, with mean (standard deviation) ages of 10.44 (0.92) years and 10.61 (0.73) years, respectively. After 1 year, myopia progression and axial elongation were all significantly less in the MYOGEN group than in the SVL group (SER change: -0.80 ± 0.44 D and -1.06 ± 0.51 D, respectively; AL change: 0.25 ± 0.15 mm and 0.37 ± 0.18 mm, respectively; all P < 0.001). Among patients with good compliance (≥8 hours/day and ≥5 days/week), the treatment effect was even more pronounced for SER (adjusted difference: 0.40 D [95% confidence interval [CI], 0.25 to 0.56]) and AL (adjusted difference: -0.15 mm [95% CI, -0.21 to -0.10]). No significant between-group differences were observed in compliance with spectacle wear and subjective visual quality.
Conclusions:
Compared with the SVL, MYOGEN was shown to reduce myopia progression and axial elongation over the 1-year follow-up period.
Financial Disclosures:
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Related Concept Videos
01:16Focusing of Light in the Eye
01:28Angle Closure Glaucoma: Treatment
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:25Glaucoma: Overview